Early regression of coronary artery remodeling with esmolol and DDAH/ADMA pathway in hypertensive rats

Hypertension Research

Volumn 39, Issue 10, 2016, Pages 692-700

  Quintana Villamandos, Begoña ^a,b   Arnalich Montiel, Ana ^a   Arribas, Silvia ^c   Lüneburg, Nicole ^d   Böger, Rainer H ^d   Delgado Martos, María Jesús ^a   Fernández Criado, Carmen ^c   Delgado Baeza, Emilio ^a   González, María Carmen ^c  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

ADMA; coronary artery; esmolol; remodeling; spontaneously hypertensive rat

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; 6 N,N' DIMETHYLARGININE; DIMETHYLARGININASE; ESMOLOL; GLYCERYL TRINITRATE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; SEROTONIN; AMIDASE; ARGININE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; N,N-DIMETHYLARGININE; PROPANOLAMINE DERIVATIVE;

ADULT; AMINO ACID BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; BIOAVAILABILITY; CELL COUNT; CONTROLLED STUDY; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MORPHOLOGY; NONHUMAN; RAT; RAT MODEL; SMOOTH MUSCLE CELL; VASCULAR REMODELING; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD PRESSURE; CORONARY BLOOD VESSEL; DOSE RESPONSE; DRUG EFFECTS; HYPERTENSION; METABOLISM; PATHOLOGY; PHYSIOLOGY; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR KYOTO RAT;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; AMIDOHYDROLASES; ANIMALS; ARGININE; BLOOD PRESSURE; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION; MALE; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE; PROPANOLAMINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SEROTONIN; VASCULAR REMODELING;

EID: 84989899187     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2016.57     Document Type: Article

References (43)

1. Garnock-Jones KP. Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension. Drugs 2012; 72: 109-132.
2. Wiest DB, Haney JS. Clinical pharmacokinetics and therapeutic efficacy of esmolol. Clin Pharmacokinet 2012; 51: 347-356.
3. Landoni L, Turi S, Biondi-Zoccai G, Bignami E, Testa V, Belloni L, Cornero G, Zangrillo A. Esmolol reduces perioperative ischemia in noncardiac surgery: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth 2010; 24: 219-229.
4. Quintana-Villamandos B, Delgado-Martos MJ, Sanchez-Hernandez JJ, Gómez de Diego JJ, Fernández-Criado MC, Canillas F, Martos-Rodríguez A, Delgado-Baeza E. Early regression of left ventricular hypertrophy after treatment with esmolol in an experimental rat model of primary hypertension. Hypertens Res 2013; 36: 408-413.
5. Yu SK, Tait G, Karkouti K, Wijeysundera D, McCluskey S, Beattie S. The safety of perioperative esmolol: a systematic review and meta-analysis of randomized controlled trials. Anesth Analg 2011; 112: 267-281.
6. Rehman A, Schiffrin EL. Vascular effects of antihypertensive drug therapy. Curr Hypertens Rep 2010; 12: 226-232.
7. Feihl F, Liaudet L, Levy BI, Waeber B. Hypertension and microvascular remodelling. Cardiovas Res 2008; 78: 274-285.
8. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, Tripepi G, Tech S, Sesti G, Zoccali C. Asymmetric dimethylarginine, L-Arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005; 46: 518-523.
9. Meinitzer A, Kielstein JT, Pilz S, Drechsler C, Ritz E, Boehm BO, Winkelmann BR, März W. Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem 2011; 57: 112-121.
10. Siegerink B, Maas R, Vossen CY, Schwedhelm E, Koenig W, Böger R, Rothenbacher D, Brenner H, Breitling LP. Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study. Clin Res Cardiol 2013; 102: 193-202.
11. Arnalich-Montiel A, González MC, Delgado-Baeza E, Delgado-Martos MJ, Condezo-Hoyos L, Martos-Rodríguez A, Rodríguez-Rodríguez P, Quintana-Villamandos B. Short-term esmolol improves coronary artery remodeling in spontaneously hypertensive rats through increased nitric oxide bioavailability and superoxide dismutase activity. Biomed Res Int 2014; 2014: 531087.
12. Koprdova R, Cebova M, Kristek F. Long-term effect of losartan administration on blood pressure, heart and structure of coronary artery of young spontaneously hypertensive rats. Physiol Res 2009; 58: 327-335.
13. Sharifi AM, Li JS, Endemann D, Schiffrin EL. Effects of enalapril and amlodipine on small-artery structure and composition, and on endothelial dysfunction in spontaneously hypertensive rats. J Hypertens 1998; 16: 457-466.
14. Neglia D, Fommei E, Varela-Carver A, Mancini M, Ghione S, Lombardi M, Pisani P, Parker H, D'amati G, Donato L, Camici PG. Perindopril and indapamide reverse coronary microvascular remodelling and improve flow in arterial hypertension. J Hypertens 2011; 29: 364-372.
15. Conde MV, Gonzalez MC, Quintana-Villamandos B, Abderrahim F, Briones AM, Condezo-Hoyos L, Regadera J, Susin C, Gomez de Diego JJ, Delgado-Baeza E, Diaz-Gil JJ, Arribas SM. Liver growth factor treatment restores cell-extracellular matrix balance in resistance arteries and improves left ventricular hypertrophy in SHR. Am J Physiol Heart Circ Physiol 2011; 301: H1153-H1165.
16. Conde MV, Marín J, Balfagón G. Superoxide anion and K+ channels mediate electrical stimulation-induced relaxation in the rat basilar artery. Eur J Pharmacol 1999; 372: 179-186.
17. Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Böger RH. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 2005; 51: 1268-1271.
18. Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, Böger RH. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 851: 211-219.
19. Maas R, Tan-Andreesen J, Schwedhelm E, Schulze F, Böger RH. A stable-isotope based technique for the determination of dimethylarginine dimethylaminohydrolase (DDAH) activity in mouse tissue. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 851: 220-228.
20. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reservein genetic hypertension: Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 1991; 69: 107-115.
21. Hüsken BC, van der Wal AC, Teeling P, Mathy MJ, Mertens MJ, Pul AJ, Pfaffendorf M, van Zwieten PA. Heterogeneity in morphological characteristics of coronary arteries and aortae in various models of hypertension. Blood Press 1997; 6: 242-249.
22. Rey FE, Pagano PJ. The reactive adventicia: fibroblast oxidase in vascular function. Arterioescler Thromb Vasc Biol 2002; 22: 1962-1971.
23. Su W, Guo Z, Deschepper CF, Randall DC, Gong MC. Dissociation of coronary artery contractile hyperreactivity from hypertension. Am J hypertens 2003; 16: 570-576.
24. Roque FR, Briones AM, García-Redondo AB, Galán M, Martínez-Revelles S, Avendaño MS, Cachofeiro V, Fernandes T, Vassallo DV, Oliveira EM, Salaices M. Aerobic exercice reduces oxidative stress and improves vascular changes of small mesenteric and coronary arteries in hypertension. Br J Pharmacol 2013; 168: 686-703.
25. Vázquez-Pérez S, Navarro-Cid J, de las Heras N, Cediel E, Sanz-Rosa D, Ruiloque LM, Cachofeiro V, Lahera V. Relevance of endothelium-derived hyperpolarizing factor in the effects of hypertension on rat coronary relaxations. J Hypertens 2001; 19: 539-545.
26. Bernatova I. Endothelial dysfunction in experimental models of arterial hypertension: Cause or consequence? Biomed Res Int 2014; 2014: 598271.
27. Miki S, Takeda K, Hatta T, Harada S, Kido H, Oguni A, Moriguchi J, Morimoto S, Kawa T, Sasaki S, Nakagawa M. Comparative effects of candesartan and enalapril on augmented vasoconstrictive responses to endothelin-1 in coronary vessels of spontaneously hypertensive rats. Am J Hypertens 2002; 15: 286-290.
28. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991; 83: 1771-1779.
29. Kang S, Woo HH, Kim K, Lim KM, Noh JY, Lee MY, Bae YM, Bae ON, Chung JH. Dysfunction of vascular smooth muscle and vascular remodeling by simvastatin. Toxicol Sci 2014; 138: 446-556.
30. Duguay D, deBlois D. Differential regulation of Akt, caspases and MAP kinases underlies smooth muscle cell apoptosis during aortic remodelling in SHR treated with amlodipine. Br J Pharmacol 2007; 151: 1315-1323.
31. Fiedler L. The DDAH/ADMA pathway is a critical regulator of NO signalling in vascular homeostasis. Cell Adh Migr 2008; 2: 149-150.
32. Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev 2010; 6: 82-90.
33. Cooke JP. ADMA: its role in vascular disease. Vasc Med 2005; 10(Suppl 1): S11-S17.
34. Bai Y, Hui R. Dimethylarginine dimethylaminohydrolase (DDAH)-A critical regulator of hypertensive left ventricular hypertrophy? Med Hypotheses 2008; 70: 962-966.
35. Asanuma H, Sanada S, Asakura M, Asano Y, Kim J, Shinozaki Y, Mori H, Minamino T, Takashima S, Kitakaze M. Carperitide induces coronary vasodilation and limits infarct size in canine ischemic hearts: role of NO. Hypertens Res 2014; 37: 716-723.
36. Li D, Xia K, Li NS, Luo D, Wang S, Jiang DJ, Deng HW, Li YJ. Reduction of asymmetric dimethylarginine involved in the cardioprotective effect of losartan in spontaneously hypertensive rats. Can J Physiol Pharmacol 2007; 85: 783-789.
37. Wang Y, Zhang M, Liu Y, Liu Y, Chen M. The effect of nebivolol on asymmetric dimethyl-arginine system in spontaneously hypertensive rats. Vasc Pharmacol 2011; 54: 36-43.
38. Bertera FM, Del Mauro JS, Lovera V, Chiappetta D, Polizio AH, Taira CA, Höcht C. Enantioselective pharmacokinetics and cardiovascular effects of nebivolol in L-NAME hypertensive rats. Hypertens Res 2014; 37: 194-201.
39. Garbin U, Pasini AF, Stranieri C, Manfro S, Boccioletti V, Cominacini L. Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylargi-nine dimethylaminohydrolase 2 (DDAH2) expression and activity. Pharmacol Res 2007; 56: 515-521.
40. Benfield P, Sorkin EM. Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drug 1987; 33: 392-412.
41. Schwartz M, Michelson EL, Sawin HS, MacVaugh H 3rd. Esmolol: safety and efficacy in postoperative cardiothoracic patients with supraventricular tachyarrhythmias. Chest 1988; 93: 705-711.
42. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38: 581-587.
43. Agabiti-Rosei E. Structural and functional changes of the microcirculation in hypertension: influence of pharmacological therapy. Drugs 2003; 63: 19-29.